Table 1 Chronological history of Hib conjugate vaccines available in the United Kingdom (1992–2006)
YearVaccineComment
1992ActHIBSingle component Hib conjugate vaccine with polyribosyl-ribitol-phosphate (PRP) covalently bound to tetanus toxoid (PRP-T) tested and used in the accelerated infant immunisation programme
HibTITERSingle component Hib conjugate vaccine with PRP covalently bound to diphtheria CRM197 protein (HbOC) used for older children in the 1992 catch-up programme for children
1996ActHIB with DTwPCombination vaccine containing Hib (PRP-T) and DTwP, given as a single injection
HibTITER with DTwPHbOC vaccine mixed with diphtheria, tetanus and whole-cell pertussis vaccine (DTwP) and given as a single injection
1997Trivax-HibCombination vaccine containing Hib (PRP-T) and DTwP, given as a single injection
1999InfanrixDiphtheria, tetanus and acellular pertussis vaccine (DTaP) combined with Hib (PRP-T) conjugate vaccine
2003Infanrix, withdrawnAcellular pertussis component shown to induce poor immunity to Hib in clinical studies, therefore withdrawn
2003Hiberix licensedHib (PRP-T) vaccine used as booster dose in 2003 campaign
2004PediaceFive-component vaccine containing DTaP, inactivated polio and Hib (PRP-T) introduced into primary immunisation programme
2006MentorixCombined meningococcal C and Hib (PRP-T) conjugate vaccine replaced the single Hib vaccine, Hiberix
  • DTaP, diphtheria, tetanus and acellular pertussis vaccine; DTwP, diphtheria, tetanus and whole-cell pertussis vaccine; Hib, Haemophilus influenzae serotype b; HbOC, Hib conjugate vaccine with PRP covalently bound to diphtheria CRM197 protein; PRP, polyribosyl-ribitol-phosphate; PRP-T, polyribosyl-ribitol-phosphate covalently bound to tetanus toxoid.